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Abstract
Archetype SV40, obtained directly from its natural host, is characterized by a single 72-bp enhancer element. In contrast, SV40 grown
in cell culture almost invariably exhibits partial or complete duplication of the enhancer region. This distinction has been considered
important in studies of human tumor material, since SV40-associated tumor isolates have been described having a single enhancer region,
suggesting natural infection as opposed to possible contamination by laboratory strains of virus. However, the behavior of archetypal SV40
in cultured cells has never been methodically studied. In this study we reengineered nonarchetypal 776-SV40 to contain a single 72-bp
enhancer region and used this reengineered archetypal DNA to transfect a number of simian and human cell lines. SV40 DNA recovered
from these cells was analyzed by restriction endonuclease analysis, PCR, and DNA sequencing. Reengineered archetype SV40 propagated
in green monkey TC-7 or BSC-1 kidney cells remained without enhancer region duplication even after extensive serial virus passage.
Archetype SV40 grown in all but one of the rhesus or human cell lines initially appeared exclusively archetypal. However, when virus from
these cell types was transferred to green monkey cells, variants with partial enhancer duplication appeared after as little as a single passage.
These findings suggest (1) that virus with a single 72-bp enhancer may persist in cultured cells of simian and human origin; (2) that variants
with partially duplicated enhancer regions may arise within cell lines in quantities below limits of detection; (3) that these variants may enjoy
a selective advantage in cell types other than those from which they arose (e.g., green monkey kidney cells); and (4) that certain cell lines
may support a selective growth advantage for the variants without supporting their formation. Our data indicate that enhancer duplication
may also occur in human as well as rhesus kidney cells. Thus, detection of enhancer region duplication may not, a priori, indicate laboratory
contamination, nor does detection of a single 72-bp enhancer exclude the possibility that contamination may have occurred. These findings
may be of relevance to studies attempting to detect SV40 DNA in human tumors or other clinical specimens.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
SV40 is a simian polyomavirus which was initially iden-
tified as a contaminant of the rhesus monkey kidney cells
used to prepare Salk and Sabin polio vaccines (Sweet and
Hilleman, 1960; Shah and Nathanson, 1976). The virus was
discovered through its ability to cause tumors in experimen-
tal animals, and this observation raised concerns that the
virus might also cause neoplasia in humans (Eddy et al.,
1961; Shah and Nathanson, 1976; Butel and Lednicky,
1999). Epidemiological studies of tumor prevalence have,
for the most part, failed to support a role for SV40 as an
agent of human neoplasia (Greenlee and O’Neill, 2002).
However, detection of SV40 nucleic acid sequences has
been reported in a variety of human tumors, including
ependymomas, mesotheliomas, osteogenic sarcomas, and
more recently in non-Hodgkin lymphoma (Soriano et al.,
1974; Geissler et al., 1985; Bergsagel et al., 1992; Carbone
et al., 1994, 1997; Martini et al., 1996; Lednicky et al.,
1997; Butel and Lednicky, 1999; Butel et al., 1998; Pacini
et al., 1998; Martin and Li, 1991a; Stewart et al., 1998;
Shivapurkar et al., 2002; Vilchez et al., 2002).
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Although SV40 was initially recovered from cultures of
kidney cells derived from its natural host, rhesus monkeys,
the virus was subsequently found to produce cytopathic
effect (CPE)—and therefore be easier to study—in contin-
uous lines of green monkey kidney (GMK) cells (Sweet and
Hilleman, 1960; Norkin and Ouellette, 1976). Virus adapted
to grow in laboratory GMK cells, such as reference strain
SV40-776, has been referred to as “wild-type virus,” to
differentiate it from strains of SV40 manipulated in vitro
(Tooze, 1980). With the advent of molecular virological
techniques, however, laboratory strains of SV40 have been
found to differ from virus recovered directly from rhesus
monkeys in that strains grown in GMK cells often have a
tandem duplication of the 72-bp enhancer (Stewart et al.,
1998). In contrast, direct isolates from rhesus monkeys have
either a single enhancer (so-called “archetypal” SV40) or,
occasionally a partial enhancer duplication but rarely a
complete duplication (Lednicky et al., 1998; Newman et al.,
1998). Studies by Gruss and colleagues on enhancer func-
tion have shown that infectivity is not reduced by deletion
of one of the two enhancers but can be abolished by dele-
tions extending into the second enhancer (Gruss, 1984). An
important observation as relates to human disease and neo-
plasia is that SV40 nucleic acid sequences obtained from
human brain tumors and osteosarcomas often have a single,
nonduplicated enhancer. This has been taken to suggest that
SV40 DNA sequences recovered from human tumors do not
represent laboratory-derived strains of virus (Lednicky and
Butel, 1997; Stewart et al., 1998).
The presence of a duplicated enhancer element in labo-
ratory SV40 versus archetypal SV40 raises several ques-
tions. First, is duplication of the enhancer region an event
which occurs strictly in cultured cells, or does the archetypal
SV40 found in nature exist along with a small amount of
nonarchetypal variants which have a selective advantage
during growth in the laboratory? Second, is duplication of
the enhancer region a uniform occurrence in cultured cells,
regardless of the cell-culture system employed, or does
duplication of the enhancer occur in some cell-culture sys-
tems but not in others? Alternatively, does growth of SV40
in cultured cells ever result in propagation of virus which
maintains a single enhancer region? Finally, if duplication
of the SV40 enhancer region occurs to form new variants
during laboratory propagation of the virus, do the variants
have a growth advantage and in which cells is the advantage
expressed? To address these questions, we reengineered
“wild-type” SV40 strain 776 to contain only a single 72-bp
enhancer, identical to that in archetypal SV40. We propa-
gated the reengineered archetype virus in a variety of simian
and human cells and then studied the development of nonar-
chetypal variants with enhancer duplications.
Results
Growth of “archetype” SV40 (reengineered 776-SV40) in
monkey cells
In our initial experiments, viral DNA was transfected and
virus was passed in human cells or rhesus monkey kidney
cells and then transferred to green monkey kidney cells
(TC-7 or BSC-1 cells) to mimic events which might have
occurred when SV40 strains were inadvertently grown in
kidney cells obtained from persistently infected culture rhe-
sus monkey (Sweet and Hilleman, 1960). (See Table 1 for a
description of the cell lines.) In other experiments, arche-
type and nonarchetype 776-SV40 DNA were transfected
into TC-7 or BSC-1 cells and then serially passed in these
cells exclusively. During virus passage in the different cell
types, the viral DNA was recovered and analyzed by several
methods to determine if the enhancer had duplicated.
Our findings were less straightforward than we had an-
ticipated. In control experiments, SphI digestion of nonar-
chetypal 776-SV40 DNA, which cleaves only in the viral
Table 1
Human and simian cells infected with SV40
Cell line Species Tissue Permissiveness for SV40 Reference
TC-7 Green monkey Kidney Archetype  nonarchetype
Complete cell destruction
Hopps et al., 1963
BSC 1 Green monkey Kidney Archetype  nonarchetype
Complete cell destruction
Robb and Huebner, 1973
LLcMK2 Rhesus monkey Kidney Archetype  nonarchetype
Little or no cell destruction
Norkin, 1976
A172 Human Glioblastoma Archetype  nonarchetype
Moderate cell destruction
O’Neill et al., 1982
AT357 Human Bronchogenic carcinoma Archetype  nonarchetype
Moderate cell destruction
O’Neill and Carroll, 1981
AM971 Human Rhabdomyosarcoma Archetype  nonarchetype
Moderate cell destruction
O’Neill and Carroll, 1981
HFB Human Fetal brain spongioblasts Archetype  nonarchetype
Extensive cell destruction
O’Neill and Carroll, 1981
HFF Human Fetal fibroblasts Archetype  nonarchetype
Minimal cell destruction
This work
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enhancer, resulted in the appearance of the characteristic
72-base-pair (bp) fragment indicative of a duplicated en-
hancer region (Fig. 1, lane 6). As expected, no similar
fragment appeared following SphI digestion of reengineered
archetypal DNA as it contains only a single SphI recogni-
tion site (Fig. 1, lane 5). DNA from archetype SV40 in-
fected BSC-1 or TC-7 green monkey kidney cells appeared
to remain archetypal, as indicated by SphI endonuclease
digestion (Fig. 1, lane 5). Southern analysis of SphI digests
also indicated that the enhancer remained unduplicated (Fig.
2, lane 9). Enhancers of the archetypes passaged in TC-7 or
BSC-1 cells were PCR amplified using regulatory region
primers and then analyzed by DNA sequencing. Using PCR,
we found only a single, faster moving band, consistent in
mobility with a DNA fragment from the archetype (Fig. 3A,
lane 2; 3B, lanes 4 and 5). This apparent maintenance of the
archetype was observed even when archetype SV40 was
passaged for at least 10 times in TC-7 green monkey kidney
cells. In contrast, when nonarchetypal 776-SV40 control
DNA was subjected to the same reaction with the same
primers, only a slower migrating DNA band was detected,
whose mobility indicated the presence of two enhancers
(Fig. 3A; lane 1). Finally, to confirm that the faster moving
viral DNA was indeed the archetype, we recovered viral
DNA after the virus was passed 10 times in TC-7 cells,
cloned 15 regulatory region molecules, and sequenced
them. Again, there was clear evidence that the DNA mole-
cules were exclusively archetypal: all of the molecules con-
tained a single 72-bp enhancer and no mutations were de-
tected elsewhere in the regulatory region (Fig. 4, map 10).
Growth of archetype SV40 (reengineered 776-SV40) in
rhesus and human cell cultures
We next studied the biological behavior of archetype SV40
DNA following transfection and passage in the rhesus monkey
(LLcMK2) cell line and in a variety of human cell-culture
systems, including human fetal brain, human glioblastoma, and
other human tumor cell lines described in Table 1. Initially, it
appeared that the archetype remained unaltered in almost all of
these cell-culture systems. However, when SphI digests from
archetype-infected HFB cells were subjected to Southern anal-
ysis, a fragment approaching the size of 72 bp could sometimes
be detected, suggesting duplication of the enhancer region in a
minority of viral DNAs (Fig. 2, lanes 2–4). With subsequent
serial passages of the HFB cell-derived virus in TC-7 or BSC-1
cells, these variants rose to a level where they represented a
major portion of the viral DNA. This was indicated by the
appearance of a DNA band at the position of approximately 72
bp in an SphI digest (Fig. 2, lanes 6 and 7). These bands, with
some exceptions, comigrated with the band produced by SphI
digestion of laboratory 776-SV40 DNA propagated in TC-7
cells and 776-SV40 recombinant plasmids (Fig. 2, lanes 3 and
4).
Similar observations were made when the viral DNAs
from HFB and several other human and rhesus cells were
analyzed by PCR, using the primers which amplify the viral
regulatory region (Fig. 3). The regulatory region fragments
recovered from these cells mostly contained one enhancer
and moved ahead of the position of the DNA fragment
which contained a duplicated or partially duplicated en-
hancer (Fig. 3A, lanes 1–7). Nevertheless, after one to four
additional virus passages in TC-7 or BSC-1 cells, the great
majority of the viral genomes contained a duplicated en-
hancer (Fig. 3A, lanes 8–10 and 12; 3B, lane 3). This
suggested that, when archetype SV40 DNA was propagated
first in human fetal brain, human tumor, or rhesus monkey
kidney cells, some of the viral DNAs—perhaps a low per-
centage of the total—had acquired duplicated enhancers.
However, unless the virus was then passed in green monkey
kidney cells, these variants were overshadowed by the ar-
chetype and were not present in sufficient numbers to be
clearly visualized by SphI digestion or by PCR analysis of
viral DNA recovered from the Hirt supernatant. An excep-
tion to this was the growth of the archetype in human
AT357 tumor cells: in some instances in this cell-culture
system, duplications of the enhancer region were detected
even prior to passage in GMK cells (Fig. 3B, lane 6).
Fig. 1. SphI endonuclease digestion of archetype SV40 DNA from infected
cells. Archetype viral DNA was transfected into A172, AT357, AM971, and
TC-7 cells. After three passages, virus was transferred to TC-7 or BSC-1 cells
as indicated and passed twice more. Archetype SV40 was also passed in TC-7
cells exclusively. After passage in human and simian cells, viral DNA was
purified from the Hirt supernatant and digested with SphI followed by elec-
trophoresis in agarose gels (O’Neill and Carroll, 1978). The appearance of a
fragment which comigrates with a SphI fragment from digested nonarchetype
776-SV40 recombinant plasmid DNA (lanes 1–4) indicates duplication of the
enhancer. This occurred in all lanes except TC-7 cells infected with archetype
SV40 (lane 5), not previously grown in human tumor cells. Lane 5 represents
viral DNA after four serial passages. Lane 6 contains 776-SV40/pUC19
recombinant DNA. Size standards, from the top are as follows: 993, 823, 673,
552, 444, 369, 311, 249, 200, 127, 100 bp.
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To confirm the existence of the viral DNA with a dupli-
cated enhancer, we sequenced the enhancer region of the
viral DNA recovered from green monkey TC-7 cells where
the variants appeared in relatively large numbers. These
analyses confirmed the existence of a duplicated enhancer
(Fig. 4, maps 4–6, 8, and 9). This duplication, although
similar to that of laboratory 776-SV40 DNA, was not exact
in that it often contained small deletions or small insertions
of 14–46 bp (Fig. 4, maps 4–6, 8, and 9). DNA sequence
analysis of the insertions indicated that they were derived
from other parts of the regulatory region (not shown). These
anomalies may have arisen by larger duplications of a
genomic region larger than the enhancer itself, followed by
deletions within this larger duplicated fragment. Variation
in SV40 enhancer(s) has also been observed in viral DNA
recovered from human brain tumors and diseased kidneys
(Martin and Li, 1991b; Li et al., 2002). However, all of the
variants identified in the present work are apparently unique
from those described by others.
Archetype viral DNA was also introduced into human
fetal fibroblasts (HFF) and propagated for 6–8 weeks. The
virus was then propagated in green monkey TC-7 cells and
viral DNA analyzed by SphI digestion. In contrast to other
human and rhesus cells, duplication of the enhancer ele-
ments could not be detected (Fig. 3A, lanes 6). This was
confirmed by DNA sequencing which demonstrated an ex-
act copy of one 72-bp enhancer element (not shown). As we
have observed previously, SV40 propagates to low-to-mod-
erate levels in human fibroblasts (O’Neill et al., 1998b). If
enhancer duplication occurs in a low percentage of the viral
DNA molecules, then this may explain why no enhancer
duplications occurred even when HFF-propagated virus was
transferred to GMK cells.
Coinfection of cells with archetype and nonarchetype
776-SV40
None of the nonarchetypal variants generated during our
experiments contained complete enhancer duplications as
exists in 776-SV40. Rather, the variants which we recov-
ered contained partially duplicated enhancers or duplicated
enhancers with insertions of other viral elements. This find-
ing was unexpected and raised questions as to whether the
growth of variants with exact enhancer duplication, such as
776-SV40, might not compete effectively with that of ar-
chetype virus such that the variants remain undetectable.
Alternatively, 776-SV40 may fail to compete only with
those newly arising variants having partial duplications. To
test the ability of 776-SV40 to compete with archetype, we
productively coinfected TC-7 cells with both archetype and
776-SV40 such that there was an excess (10- to 10,000-fold
more) of archetype virus. The virus was then serially passed
in GMK, TC-7, or BSC-1 cells. After each passage the viral
DNA was assayed by PCR for the presence of enhancer
elements. The PCR products were then subjected to agarose
gel electrophoresis. High levels of 776-SV40 were detected,
indicating that 776-SV40 had competed with and over-
grown the archetype (Fig. 5). In addition, the competitive
advantage of 776-SV40 was observed within just a few
passages in GMK cells and was sometimes observed in only
one passage (Fig. 5, lane 1). We found also that the appear-
ance of the growth advantage of 776-SV40 was somewhat
Fig. 2. Southern analysis of SphI digests of archetype SV40 DNA recovered from infected human fetal brain (HFB spongioblasts) cells. Infection, recovery,
and SphI digestion of viral DNA were as described under the Materials and Methods and in Fig. 1. SV40 DNA was then subjected to agarose gel
electrophoresis. For Southern blotting, the DNA was transferred to Nytran membranes and then hybridized with SV40 DNA probes labeled with [32P]dCTP
as described (O’Neill et al., 1998a). A band approximating the position of the enhancer appeared in viral DNA recovered from HFB cells (lanes 3 and 4).
However, in lanes 3, 4, 6, and 7, the band appears to migrate slightly behind that from nonarchetype 776-SV40 DNA shown in lanes 5 and 10. These slower
migrating bands may contain duplications with insertions of other viral sequences, some of which are described in Figs. 3–5. No band was detectable in viral
DNA recovered from archetype SV40-infected HFF cells or after this virus was passed in TC-7 cells (lanes 8 and 9). In lane 10 the recombinant plasmid
DNA was greatly overloaded.
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dependent on the relative amount of archetype that may
have been present in coinfected cells. When this was re-
duced by dilution of the infecting virus pool, 776-SV40
seemed to appear more quickly (Fig. 5). Consequently, we
regard 776-SV40 as a variant able to effectively compete
with archetype SV40 in terms of growth.
Fig. 3. PCR analysis of the SV40 regulatory region after serial passages of archetype SV40 in various humans, rhesus, and green monkey kidney cells.
Archetype SV40 DNA was transfected into cells resulting in a productive infection. Virus was then serially passed in the same cells or transferred to TC-7
or BSC-1 cells for two to four more passages. The viral DNA was recovered and then subjected to PCR and electrophoresis as under Materials and methods.
The amplified DNA was then focused by agarose gel electrophoresis for a sufficient period to cause separation of bands containing one and two enhancers.
(A) DNAs from archetype and nonarchetype controls and DNAs from archetype virus passed several times in various cell lines, and then after subsequent
propagation in TC-7 cells. Lanes 1 and 2 contain DNAs from 776-SV40 and the archetype SV40 and show the positions for the regulatory region with and
without a duplicated enhancer. Lane 3: HFB cells, passage 8; lane 4: AM971 cells, passage 3; lane 5: AT357 cells, passage 3; lane 7: LLcMK2 cells, passage
5; lanes 6 and 8–12 contain archetype SV40 from infected human or rhesus cells after propagation in TC-7 cells. Note also that the viral DNA band from
HFB cells (A, lane 3) appears slightly below the archetype position. We believe it contains a small regulatory region deletion which is being characterized.
In (B) appears DNA recovered from archetype-infected TC-7 cells at passage 8 (lane 4) and passage 10 (lane 5), showing no enhancer duplication. Lane 3
shows bands at both positions after recovery of DNA from virus passed from HFB to TC-7 cells. It represents a separate experiment from that shown in (A),
lane 8. In (A, lane 9) a double band exists near the position for a duplication and indicates that in AM971 cells at virus passage 4, new variants migrating
at different positions have appeared. See also B, lane 6. Note that (A, lanes 10 and 12) have bands appearing at a position between those for one and two
enhancers, along with smears of migrating DNA at other positions. These are denoted with arrows. In lane 10 of (A) very little DNA at the archetype position
is detectable. Lanes at opposite ends of (A) and the right end of (B) contain 50-bp size standard ladders. The brightest band is 350 bp. “NA” and “A” refer
to positions of nonarchetype and archetype regulatory region DNAs, respectively.
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Agarose gel analysis of DNAs from coinfected cells also
revealed new bands migrating at positions between archetype
and 776-SV40 regulatory regions (Fig. 5, lanes 2–6), as well as
bands migrating more slowly than that derived from 776-SV40
(Fig. 5, lanes 4 and 5). This suggested that additional species of
SV40 were being generated, containing new nonarchetypal
regulatory region variants. Some of these were intermediate in
size between archetype and 776-SV40 regulatory regions and
some were apparently larger than the 776-SV40 regulatory
region (Fig. 5, arrows). Novel regulatory region variants were
also observed when archetype SV40 was propagated first in
AT 357 and LLcMK2 cells and then in TC-7 cells (Fig. 3A,
lanes 10 and 12). These variants were present in significant
amounts, indicating that they were able to compete effectively
for growth with both 776-SV40 and the archetype. Because
these new variants did not appear when the archetype or
776-SV40 was propagated in TC-7 cells separately, it is prob-
able that they resulted from recombination between the two
viral DNAs.
Discussion
Inoculation of rhesus monkey kidney LLcMK2 cells
with SV40 results in high titer virus. However, this infection
results in very little CPE, and LLcMK2 cells cannot be used
for plaque assay (Sweet and Hilleman, 1960; Norkin, 1976).
In contrast, infection of green monkey kidney cell lines such
as CV-1, BSC-1, or TC-7 with laboratory strains of SV40
results in a characteristic CPE, which facilitates recognition
of virus growth and allows assay of SV40 by plaque for-
mation (Carroll and O’Neill, 1978). Consequently, green
monkey kidney cells are usually the preferred cell substrate
for virus growth in the laboratory (Sweet and Hilleman,
1960). The great majority of SV40 strains which have been
cultured in green monkey cells contain either complete or
partial tandem duplications of the 72-bp enhancer (Led-
nicky et al., 1995, 1998; Lednicky and Butel, 1997). In
contrast, SV40 often found in “naturally” infected rhesus
monkeys and that recovered from some human brain tumors
and osteosarcomas usually contains only a single 72-bp
enhancer, the SV40 archetype (Ilyinskii et al., 1992; Led-
nicky et al., 1995, 1998). These data could be taken to
indicate, perhaps erroneously, that propagation of SV40 in
GMK cell lines provides a stimulus to enhancer duplication
not seen in nature.
The present study had two main objectives. First, we
wished to determine if transition from the archetype to the
duplicated enhancer variant occurred during virus passage
in green monkey kidney cells. Second, we wished to deter-
Fig. 4. DNA sequence analysis of SV40 regulatory regions before and after acquisition of enhancer duplications. The 10 enhancer maps depict the boundaries
of each enhancer and the positions of insertions and deletions. Both enhancers were found to be involved in the occasional deletions or insertions. The
insertions were found to be derived from other elements in the regulatory region. The letters a, b, and c denote nonarchetypes which contain insertions. The
sequences of these insertions are presented at the bottom of the illustration.
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mine if duplication of the enhancer was specific or unique to
rhesus monkey, green monkey, or human cells. This would
lend support to the concept that the presence of SV40 DNA
in some forms of human cancer represented true in vivo
infection, rather than laboratory contamination. An addi-
tional issue which arose during the course of our experi-
ments was whether nonarchetypal variants might exist in
animal tissues at copy numbers too low to detect but might
then be selected when the virus was propagated in green
monkey cells. Our analyses of these questions were aided by
the unique presence of a single SphI restriction endonucle-
ase site in each of the enhancers of laboratory 776-SV40
DNA: this permitted us to engineer an archetypal form of
SV40 DNA containing a single enhancer region.
Our findings suggest that the behavior of archetypal
SV40 in culture is complex and depends not only upon the
cell-culture system used for initial viral growth but also
upon the culture systems used in subsequent passage. Thus
archetype SV40 DNA introduced into green monkey BSC-1
and TC-7 kidney cells propagated well, was stable, and did
not revert to the variant form containing two enhancers,
even during prolonged passage. Similar results were re-
ported by Stewart et al, who found no duplication after 14
passages in CV-1 green monkey kidney cells (Stewart et al.,
1998). In contrast, introduction of archetype SV40 into
permissive rhesus and human cell lines resulted in duplica-
tion of the enhancer region. In AT357 cells, nonarchetypal
variants could be detected by PCR without growth in green
monkey cells. In all other cell systems studied, enhancer
duplication was not initially apparent and could usually be
detected only after the lysate recovered from rhesus or
human cells was subsequently passed in green monkey
kidney BSC-1 or TC-7 cells. Enhancer duplication could
usually be observed within two passages in BSC-1 or TC-7
cells, suggesting that nonarchetypal viral DNAs existed in
virus preparations obtained from human or rhesus cells but
were present in quantities below our limits of routine de-
tection. In addition, the enhancer duplications were incom-
plete in virtually all cases; one of the two enhancers often
contained a deletion or an insert of from 14 to 46 bp (Fig.
4). These data suggest that enhancer duplication occurs in a
small percentage of the viral DNAs in both the rhesus and
the human cells. However, these variants may not enjoy a
replicative advantage in these cells and remain infrequent
members of the population of viral DNAs unless they are
introduced into green monkey kidney TC-7 or BSC-1 cells.
In TC-7 and BSC-1 cells they do appear to have a growth
advantage.
Fig. 5. PCR recovery of archetype and nonarchetype 776-SV40 DNAs from coinfected cells. Green monkey kidney TC-7 cells were infected with archetype
SV40 and small amounts of nonarchetype 776-SV40, such that the relative amounts of the two viruses varied. We produced a ratio of 10- to 1000-fold more
archetype virus than 776-SV40. After two to three passages at high m.o.i. (diluted 1/10) or low m.o.i. (diluted 1/10,000), the regulatory regions were analyzed
by PCR. Lanes 1–6 show the competitive growth advantage of 776 SV40, especially in lanes 1, 2, 5, and 6. In Lane 1, 776-SV40 was mixed with archetype
such that the number of infectious units were 10 archetype to 1 nonarchetype and the mixture was diluted 10,000-fold before infection. Within only a single
passage (16 days), the nonarchetype has overgrown the archetype. In lane 2 there was a 50-fold excess of the archetype but the mixture was not diluted prior
to infection. In lane 3, the viral mixture contained a 1000-fold excess of the archetype and was diluted 10-fold before infection. In lane 4 the mixture was
undiluted prior to infection. In lanes 5 and 6 there was a 100- and 20-fold more archetype in the mixture which was diluted 100 fold (lane 5) or undiluted
(lane 6) before infection. Note the appearance of novel bands in lanes 2–6 (arrowheads). Bands appearing above the position of the 776-SV40 duplicated
enhancer are present in lanes 4 (faint) and 5. This is similar to those bands appearing in Fig. 3, lanes 10 and 12.
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776-SV40, with its duplicated enhancer, represents a
prototypical example of tissue culture-derived wild-type
SV40. Studies by Lednicky et al., however, demonstrate
that nonarchetypal SV40 isolates from naturally infected
rhesus monkeys very rarely contain complete enhancer re-
gion duplications (Lednicky et al., 1998). Although our
studies demonstrated that 776-SV40 could compete effec-
tively with the archetype in coinfected green monkey kid-
ney cells, none of the nonarchetypal SV40 DNAs formed in
rhesus monkey kidney or human cell cultures contained
complete enhancer region duplications. One possible expla-
nation for the relative paucity of nonarchetypal variants
with perfect enhancer duplications in animals and rhesus
monkey LLcMK2 cells is that they represent a transition
phase from the archetype to the more common nonarche-
typal variant with partial enhancer duplications. When we
infected green monkey TC-7 cells with archetype SV40
containing small amounts of nonarchetype 776-SV40, we
could demonstrate a competitive advantage for 776-SV40.
However, when we examined the results of PCR analysis,
we found that new variants had formed which were absent
from cells infected with 776-SV40 or archetype SV40
alone. The new variants had lesser or greater gel mobility
than the PCR recovered DNA fragments from the prototype
776-SV40 regulatory region. It is likely that these variants
have formed by recombination between 776-SV40 and the
archetype. Our data suggest that new variants of SV40
produced by recombination between archetype and nonar-
chetype may enjoy a growth advantage over both archetypal
and 776-SV40 in GMK cells, but perhaps not in rhesus
monkey kidney and most permissive human cells. We are
currently isolating and characterizing these new variants.
The detection of archetype SV40 DNA in human tumors
has been considered important because it has been taken to
suggest natural infection; in contrast, detection of viral
DNAs with duplicated enhancer regions has been taken to
indicate laboratory contamination. However, our data sug-
gest a more complex scenario. First, our findings suggest
that detection of nonarchetype SV40 with a duplicated or
partially duplicated enhancer may not always represent lab-
oratory contamination, since such variants may occur dur-
ing virus growth in some human cells. Second, our data
suggest that the presence of the archetype in tissue samples
could result from contamination of virus which had been
propagated in green monkey kidney cells. This could hap-
pen if, when rhesus monkey derived virus was transferred to
green monkey cells, it was done in such small amounts that
nonarchetypal variants were excluded.
In summary, our data suggest that there are two main
types of SV40: archetypal SV40 with a single enhancer
region and variant nonarchetype strains containing a dupli-
cated enhancer. Furthermore, both types may exist in nature.
While archetype SV40 is the virus most probably transmit-
ted between rhesus monkeys (and perhaps humans), SV40
variants may arise during infection and may have a selective
advantage over the archetype in cell types other than those
which supported the initial infection. Thus far, there is
insufficient evidence to suggest that archetype SV40 or
SV40 with enhancer region duplication is oncogenic in
monkeys. The role of SV40 archetype and variant strains in
human neoplasia remains to be further explored.
Materials and methods
Growth of reference strain 776-SV40 and generation of
archetype SV40 DNA
Reference strain 776-SV40, known to contain a dupli-
cated enhancer region, was used as the basis for our studies.
776-SV40 was originally discovered in an adenovirus type
1 stock which had been passed in rhesus cells (Lednicky et
al., 1998) and had subsequently been grown in BSC-1 cells
to produce an infection (O’Neill et al., 1998a). Viral DNA
was recovered from the Hirt supernatant and cloned into
pUC19 at its EcoRI site. Virus from the recombinant pUC19
clone was used to transfer various simian and human cells to
produce an infection.
Archetype SV40 virions, containing a single enhancer
region in the viral DNA, cannot be readily obtained for
laboratory purposes, since growth in usual culture systems
has been expected to cause enhancer region duplication. For
this reason, we reengineered strain 776-SV40 to contain a
single enhancer region. Our approach was based on the
finding that each element of the 776-SV40 tandem duplica-
tion of the 72-bp viral enhancer contains an SphI endonu-
clease restriction site. The SphI site is found nowhere else in
the viral genome and excision of the genome with SphI will
remove one of the enhancer elements while leaving the viral
genome otherwise intact. In these experiments, 776-SV40
DNA was cleaved with SphI, and the resultant 72-bp frag-
ment was “discarded.” The large 5171-bp fragment was
then self-ligated with T4 DNA ligase, yielding a genome
with a single 72-bp enhancer element. The genome was then
cloned into pUC19 at the EcoRI site or pSVneo at the EcoRI
site. DNA sequence analysis demonstrated that the reengi-
neered archetype contained only a single 72-bp enhancer.
Cloning at the EcoRI site did not interrupt the T-Ag gene.
Cell-culture systems
Table 1 lists the cell lines used for growth of archetype
SV40 and its variants. TC-7 and BSC-1 are established
green monkey kidney cell lines which are highly permissive
for SV40 lytic growth and produce high titers of SV40
(Hopps et al., 1963; Carroll and O’Neill, 1978). LLcMK2 is
a rhesus monkey kidney cell line which also supports pro-
ductive SV40 infection but in which SV40 produces little
cell killing (Sweet and Hilleman, 1960; Norkin, 1976). HFB
96271 is a strain of human fetal brain cells (spongioblasts)
derived as previously described (O’Neill and Carroll, 1978).
AM971, AT357, and A172 are human rhabdomyosarcoma,
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bronchogenic carcinoma, and glioblastoma cell lines de-
scribed previously, all of which support SV40 lytic growth
(O’Neill and Carroll, 1978; O’Neill et al., 1982). HFF
96123 is a strain of human fibroblasts isolated from fetal
human tissue: these cells are semipermissive for SV40
growth. All cells and cell lines were propagated in minimum
essential Eagle’s medium supplemented with 5% calf se-
rum.
DNA transfection
Archetype SV40-776 DNA was cleaved from pUC19
and self-ligated, and 1 g was transfected into cells using
the calcium phosphate procedure (Carroll and O’Neill,
1978). To reduce toxicity of the transfection procedure for
human cells, we reduced the Bis buffer concentration to
60–75% of normal.
Recovery and analysis of viral DNA
For cells in which SV40 produced CPE, we isolated and
purified the viral DNA directly from cells by Hirt extraction
when CPE became extensive (Carroll and O’Neill, 1978). In
several experiments the virus present in the supernatant
medium was saved and passed once or several more times in
cells, prior to isolation of viral DNA. SV40 causes very
little, if any, CPE in LLcMK2 cells. Here, we recovered
DNA from Hirt supernatants at 4–8 weeks following infec-
tion.
In initial experiments, purified viral DNA was analyzed
for the presence of a duplicated enhancer by SphI digestion
or by Southern blot analysis. SphI digestion produced a
72-bp fragment only if the enhancer has duplicated. Because
small fragments are sometimes difficult to visualize and
because not all the viral DNA molecules contained the
duplication, the digests were analyzed on polyacrylamide
gels rather than by agarose gel electrophoresis. Southern
analysis was used to detect instances in which only a frac-
tion of the viral DNA molecules contained a duplicated
enhancer. In some instances, growth of SV40 in human cells
resulted in the generation of defective DNAs, making gel
analysis difficult (O’Neill and Carroll, 1981). Passage of
virus to fresh, naı¨ve cells after dilutions of up to 10,000-fold
reduced levels of defective genomes but did not eliminate
molecules with enhancer duplications. In these instances,
we subjected viral DNAs to PCR analysis using primers
specific for the viral regulatory region containing the en-
hancers. As regulatory region DNA molecules with dupli-
cated enhancers were larger, they moved more slowly dur-
ing electrophoresis and appeared as a band above the
archetype: we found that this method mirrored our results
with SphI cleavage analysis, was more reliable, and gave a
more unambiguous result. Consequently, it became the pri-
mary assay in which to analyze the viral enhancer region.
This also permitted direct DNA sequencing, if needed, to
characterize the duplication (Huntsman Cancer Institute,
University of Utah). Where the presence of more than one
species of viral DNA caused the appearance of an unclear
sequence chromatogram, we first cloned SV40 DNA mol-
ecules and then had them sequenced individually.
The PCR primers that we used were nested derivatives of
RA3 and RA4 (Lednicky et al., 1998). The RA3n and RA4n
were 5 CCT CTG AAA GAG GAA CTT GGT 3 and 5
CTT TAT CCA TCT TTG CAA AGC 3, respectively, and
were used at a concentration of 10 M. One- to two-
nanogram samples of DNA were denatured at 95°C for 4
min and then cycled at 95°C for 1 min, 59°C for 1 min, and
72°C for 1 min for a total of 35 cycles. Elongation occurred
at 72°C for 7 min. The products of these reactions were then
analyzed on agarose gels by electrophoresis. The numbering
of the nucleotides was that of Buckler and Salzman (1986).
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